TARGETED THERAPY OF NSCLC WITH EGFR ACTIVATING MUTATIONS IMPROVES THE QUALITY OF LIFE OF PATIENTS
https://doi.org/10.21518/2079-701X-2016-10-56-65
Abstract
Conversion of the incurable disease in the chronic form and improvement of the life quality parameters on the background of appearance of new drugs is of specific importance for patients with NSCLC with activating mutations. “ESMO thinks that treatment of patients with wide-spread and incurable cancer forms a greater share of the oncologists work… and for these patients the quality of life is of chief importance irrespective of its duration. Use of high-precision targeted anti- EGFR therapy allows considerably improving the quality of life of oncologic patients with non-small pulmonary carcinoma with activating mutations.
About the Authors
T. Y. SEMIGLAZOVA
FSBI Petrov Oncology Scientific and Research Institute of the Ministry of Health of Russia; SBEI HPE Mechnikov NWMU of the Ministry of Health of Russia
Russian Federation
MD
Russian Federation
MD
A. S. ZHABINA
FSBI Petrov Oncology Scientific and Research Institute of the Ministry of Health of Russia; SBHI Saint-Petersburg Clinical Scientific and Practical Center of Specialized Medical Aid Types (Oncologic)
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
А. V. BELYAEVA
FSBI Petrov Oncology Scientific and Research Institute of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
V. A. KLUGE
FSBI Petrov Oncology Scientific and Research Institute of the Ministry of Health of Russia
Russian Federation
Russian Federation
K. V. USOVA
FSBI Petrov Oncology Scientific and Research Institute of the Ministry of Health of Russia
Russian Federation
Russian Federation
D. H. LATIPOVA
Russian Federation
PhD in medicine
G. M. TELETAEVA
FSBI Petrov Oncology Scientific and Research Institute of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
A. V. NOVIK
FSBI Petrov Oncology Scientific and Research Institute of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
A. I. SEMENOVA
FSBI Petrov Oncology Scientific and Research Institute of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
S. A. PROTSENKO
FSBI Petrov Oncology Scientific and Research Institute of the Ministry of Health of Russia
Russian Federation
MD
Russian Federation
MD
References
1. Семиглазова Т.Ю., Семиглазов В.В., Филатова Л.В. и др. Качество жизни – важный критерий эффективности таргетной терапии метастатического поражения скелета при раке молочной железы. Опухоли женской репродуктивной системы, 2013, 1–2: 17- 22. / Semiglazova T.Y., Semiglazov V.V., Filatova L.V. et al. Life quality is an important criterion of the skeleton metastatic lesion targeted therapy effectiveness in mammary gland cancer. Opukholi Zhenskoy Reproduktivnoy Systemy, 2013, 1-2: 17-22.
2. Указ Президента Российской Федерации от 31 декабря 2015 года №683 «О Стратегии национальной безопасности Российской Федерации» (https://rg.ru/2015/12/31/nacbezopasnost- site-dok.html). / Decree of President of the Russian Federation dated December 31, 2015, No. 683 About National Security Strategy of the Russian Federation (https://rg.ru/2015/12/31/nac-bezopasnost-sitedok. html)
3. Вассерман Л.И., Трифонова Е.А. Методология исследования качества жизни в контексте психосоматических и соматопсихических соотношений. Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева, 2006, 4: 12-15. / Vasserman L.I., Trifonova E.A. Methods to study life quality in the context of psychosomatic and somatopsychic ratios. Obozreniye Psykhiatrii I Meditsinskoy Psychologii im. V.M. Bekhtereva, 2006, 4: 12-15.
4. Семиглазова Т.Ю., Жабина А.С., Осипов М.А. и др. Качество жизни – принципиальный критерий эффективности таргетной терапии метастатического HER2-положительного рака молочной железы. Современная онкология, 2015, 17(1): 19-24. / Semiglazova T.Y., Zhabina A.S., Osipov M.A et al. Life quality – principal criterion of effectiveness of targeted therapy of metastatic HER2-positive mammary gland cancer. Sovremennaya Onkologia, 2015, 17(1): 19-24.
5. Новик А.А., Ионова Т.И., Руководство по исследованию качества жизни в медицине. Учебное пособие для ВУЗов. Под ред. акад. РАМН Шевченко Ю.Л. М.: ЗАО «ОЛМА Медиа Групп», 2007. С. 194. / Novik A.A., Ionova T.I. Guidance on Life Quality Study in Medicine. Textbook for Higher Educational Institutions. Ed. by Academician of RAMS Shevchenko Y.L. M.: CJSC OLMA Media Group, 2007, p. 194.
6. Beckman M. More clinical cancer treatments judged by progressionfree rather than overall survival. J Natl Cancer Inst, 2007, 99: 1068-9.
7. Bedard G, Zeng L, Lam H et al. Meaningful change in oncology quality-of-life instruments: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res, 2012, 12: 475-83.
8. Cella D, Pickard AS, Duh MS, et al. Healthrelated quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. Eur J Cancer, 2012, 48: 311-23.
9. Cocks K, King MT, Velikova G et al. Evidencebased guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer, 2012, 48: 1713-21.
10. Fallowfield LJ, Fleissig A. The value of progression- free survival to patients with advancedstage cancer. Nat Rev Clin Oncol, 2012, 9: 41-7.
11. Ashbury FD, Findlay H, Reynolds B et al. A Canadian Survey of Cancer Patients’ Experiences. Journal of Pain and Symptom Management, 1998, 16(5): 298-306.
12. Geater L, Chong-Rui Xu et al. Symptom and Quality of Life Improvement in LUX-Lung. An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-smallcell Lung Cancer Sarayut L, et al Journal of Thoracic Oncology ® • Volume 10, Number 6, June 2015.
13. Griebsch I, Palmer M, Fayers PM, Ellis S. Is progression- free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib. BMJ Open, 2014, 4: e005762.
14. Gutman SI, Piper M, Grant MD et al. Progression-free survival: what does it mean for psychological well-being or quality of life? AHRQ methods for effective health care. 2013. Report No.: 13-EHC074-EF. Published Online First.
15. Yang JC-H, Hirsh V, Schuler M et al. Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/ Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology, 2013, 31(27): 3342- 3350.
16. Kohler J, Schuler M. LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front line therapy for patients with metastatic EGFR-mutated lung cancer. Future Oncol, 2014 Mar, 10(4): 533-40. doi: 10.2217/fon.14.9.
17. Kaasa S. 21st ESMO Congress, Vienna, 1996. Educational book, pp. 209-212.
18. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst, 2013, 105: 595- 605.
19. Cherny NI. ESMO’s new direction in supportive and palliative care. Arch oncol, 2004, 12(3): 163-5.
20. Sherrill B, Amonkar MM, Sherif B et al. Quality of life in hormone receptor-positive HER- 2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. Oncologist, 2010, 15: 944-53.
21. Siena S, Peeters M, Van Cutsem E et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer, 2007, 97: 1469-74.
22. Sarayut LG, Chong-Rui Xu et al. Symptom and Quality of Life Improvement in LUX-Lung. An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–smallcell Lung Cancer. Journal of Thoracic Oncology, 2015 June, 10(6).
23. Zhou X, Cella D, Cameron D et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat, 2009, 117: 577-89.
24. www.fda/gov/GuidanceComplianceRegulatory Information/Guidance.
25. Passaro A, Di Maio M, Del Signore E, Gori B, de Marinis F. Management of Nonhematologic Toxicities Associated With Different EGFR-TKIs in Advanced NSCLC: A Comparison Analysis. Clinical Lung Cancer, 2014, 15(4): 307-12.
26. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 2008, 27: 4702-11.
27. Solca F, Dahl G, Zoephel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther, 2012, 343: 342-50.
28. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31: 3327-34.
29. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUXLung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15: 213-22.
30. Park K, Tan E-H et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation- positive non-small-cell lung cancer (LUXLung 7): a phase 2B, open-label, randomized controlled trial. Lancet Oncol, 2016, 17: 577-89.
31. Hirsh V, Yang JC-H, Park K et al. First-line afatinib versus gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): patient-reported outcomes and impact of dose modifications on efficacy and adverse events. Poster 369, ASCO 2016.
32. Soria J-C, Felip E et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. www.thelancet.com/ oncology. Published online July 6, 2015. http://dx.doi.org/10.1016/S1470-2045(15)00006-6.
33. Popat S, Felip E et al. Second-line afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung: patientreported outcome data from the global UXLung 8 Phase III trial. #3085. European Cancer Congress (ECC), Vienna, Austria, 25-29 September 2015.
34. Schuler M, Yang JC-H et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/ gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology, 2016, 00: 1-7, doi:10.1093/annonc/mdv597.
Review
For citations:
SEMIGLAZOVA TY, ZHABINA AS, BELYAEVA АV, KLUGE VA, USOVA KV, LATIPOVA DH, TELETAEVA GM, NOVIK AV, SEMENOVA AI, PROTSENKO SA. TARGETED THERAPY OF NSCLC WITH EGFR ACTIVATING MUTATIONS IMPROVES THE QUALITY OF LIFE OF PATIENTS. Meditsinskiy sovet = Medical Council. 2016;(10):56-65. (In Russ.) https://doi.org/10.21518/2079-701X-2016-10-56-65
Views:
774
Email this article 